Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin

SIMPLE SUMMARY: Men with metastatic castration-resistant prostate cancer (mCRPC) have shorter overall survival and resist therapy faster if their blood have a poor lipid profile. This poor lipid profile includes high levels of sphingolipids, thus reducing these sphingolipids may slow prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Mak, Blossom, Lin, Hui-Ming, Duong, Thy, Mahon, Kate L., Joshua, Anthony M., Stockler, Martin R., Gurney, Howard, Parnis, Francis, Zhang, Alison, Scheinberg, Tahlia, Wittert, Gary, Butler, Lisa M., Sullivan, David, Hoy, Andrew J., Meikle, Peter J., Horvath, Lisa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563053/
https://www.ncbi.nlm.nih.gov/pubmed/36230715
http://dx.doi.org/10.3390/cancers14194792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563053/
https://www.ncbi.nlm.nih.gov/pubmed/36230715
http://dx.doi.org/10.3390/cancers14194792

Ejemplares similares